Columbia University Vagelos College of Physicians and Surgeons

Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis

Retrieved on: 
Saturday, March 18, 2023
Neurotoxin, BA, Drug development, Columbia University Vagelos College of Physicians and Surgeons, University, Hyperhidrosis, Allergan, MBA, Uniform Securities Agent State Law Exam, Doctor of Philosophy, Aquavit, Harvard Medical School, Dermatology, Investment, Patient, Physician, Ophthalmology, FINRA, Axial, Drug discovery, Knowledge, Health, FDA, IND, Clostridium botulinum, Neurology, University of Oxford, Pharmaceutical industry, Management, MD

NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

Key Points: 
  • NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.
  • Alongside Aquavit's biosimilar program for its botulinum toxin, this will be the first in the world, indicated for palmar hyperhidrosis, approved by FDA.
  • Aquavit has been investing in proprietary delivery technologies and related intellectual property for botulinum toxin.
  • This is a strategic move that puts them ahead of the curve in the fast-growing multi-billion-dollar botulinum toxin market.

n-Lorem Foundation Welcomes New Members, Paul Compton and Neil Shneider, to its Board of Directors

Retrieved on: 
Thursday, March 2, 2023
Biotechnology, FDA, Health, Finance, Pharmaceutical, Professional Services, Philanthropy, Research, Hospitals, Fund Raising, Genetics, Foundation, Science, Clinical Trials, DSM-IV codes, Columbia University Vagelos College of Physicians and Surgeons, Drug development, Corporation, Patient, Drug discovery, ALS, Surgeon, Department of Neurology, Xuanwu hospital, Barclays, ASO, Columbia University, Investment banking, Eleanor, Asos, Physician, Disease, Hope, Neurology, Crédit Agricole Corporate and Investment Bank, Pharmaceutical industry, Nursing

Ph.D.

Key Points: 
  • Ph.D.
    “I am pleased to be joining the Board of Directors for n-Lorem Foundation.
  • For patients with nano-rare mutations, a gene-based therapy may be the most promising way to change the trajectory of their disease.
  • “Our senior leadership, scientists, support staff, and our Board believes in the extraordinary task ahead and feels the urgency to reach and provide help to nano-rare patients.
  • Watch : n-Lorem Foundation: Creating a Better Future for Nano-Rare, One Patient at a Time

Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies

Retrieved on: 
Monday, February 13, 2023
Columbia University Vagelos College of Physicians and Surgeons, Hook effect, Mouse, Blood, Human, SARS-CoV-2, Therapy, Bangladesh Technical Education Board, Tonix Pharmaceuticals, Columbia University, Patient, Epitope, Food, Risk, Knowledge, Antibody, FDA, Physician, COVID, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, Immunization, EUA, Mab, Pharmaceutical industry, Vaccine

CHATHAM, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has exercised an option to obtain an exclusive license from Columbia University for the development of a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies (mAbs) for the treatment or prophylaxis of SARS-CoV-2 infection. SARS-CoV-2 is the cause of COVID-19. The licensed mAbs were developed as part of a research collaboration and option agreement between Tonix and Columbia University, originally announced in 2020.

Key Points: 
  • The licensed mAbs were developed as part of a research collaboration and option agreement between Tonix and Columbia University, originally announced in 2020.
  • “The licensing of these mAbs strengthens our expanding pipeline of next-generation therapeutics to treat and prevent COVID-19,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • The fully human mAbs generated by Columbia University, TNX-3600, have been isolated using a proprietary system involving a human hybridoma fusion partner.
  • Dr. Lederman added, “The potential therapeutic antibodies licensed from Columbia University leverage our expanding internal development and manufacturing capabilities for biologics.

Hudson Mind Welcomes Psychiatrist Dr. Marcel Green

Retrieved on: 
Wednesday, February 8, 2023
Mental health, Hofstra University, Transcranial magnetic stimulation, PTSD, TMS, Icahn School of Medicine at Mount Sinai, Psychotherapy, Patient, Columbia University Vagelos College of Physicians and Surgeons, Columbia University, Depression, Health, Anxiety, OCD, Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Quality of life, DSB, Mount Sinai, Nursing

NEW YORK, Feb. 8, 2023 /PRNewswire/ -- Hudson Mind welcomes psychiatrist Dr. Marcel Green, M.D.

Key Points: 
  • NEW YORK, Feb. 8, 2023 /PRNewswire/ -- Hudson Mind welcomes psychiatrist Dr. Marcel Green, M.D.
  • Hudson Mind opened its doors in 2022 as the interventional mental health pillar of Hudson Health's health collective.
  • Hudson Mind is founded on an interventional approach to mental health that utilizes cutting-edge procedures to target the mental and physical symptoms of depression, anxiety, PTSD, and more.
  • Dr. Green will lead Hudson Mind's practice alongside Hudson Health founder and chief medical officer Dr. Jonathann Kuo, M.D.

Iona University Dedicates Kelly Center for Health Sciences in Bronxville

Retrieved on: 
Tuesday, January 17, 2023
Representative, Heat, Physician, SLAM, Catholic (term), Student, Surgeon, Education, Occupational therapy, Architecture, Family, Philosophy, United States House of Representatives, Columbia University Vagelos College of Physicians and Surgeons, House, Hope, Carbon, Weill Cornell Medicine, Growth, Concordia University, JLL, Archbishop, Outline of health sciences, Andrea Consigli, Interior design, Fast food, Medicine, NewYork-Presbyterian Hospital, Trustee, Visa

BRONXVILLE, N.Y., Jan. 17, 2023 /PRNewswire/ -- Iona University hosted a dedication ceremony for the Kelly Center for Health Sciences on January 12, 2023, recognizing benefactors Alfred F. Kelly Jr. '80, '81MBA, '19H, chairman and chief executive officer of Visa, and Peggy Kelly '81, '84MBA, who generously gifted $5 million to name the building.

Key Points: 
  • Iona University hosted a dedication ceremony for the Kelly Center for Health Sciences on January 12, 2023.
  • Located on Iona's new campus in Bronxville, N.Y., the Kelly Center for Health Sciences will serve as the flagship building of the NewYork-Presbyterian Iona School of Health Sciences .
  • "The legacy of the Kelly Center for Health Sciences will be built through the many thousands of Iona students who go on to save and improve lives for generations to come," said Peggy Kelly.
  • During the dedication ceremony, Iona University President Seamus Carey, Ph.D., said the opening of the Kelly Center for Health Sciences marked the beginning of a new era for Iona.

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Retrieved on: 
Thursday, January 12, 2023
Regulatory T cell, Blood, Prostate cancer, Physician, Columbia University Irving Medical Center, Surgeon, Trial of the century, MDSC, Safety, TAAS, Columbia University Vagelos College of Physicians and Surgeons, MD, PSA, Herbert Irving Comprehensive Cancer Center, NK, Columbia University, Patient, Brachytherapy, Abstract, TME, OTCQX, Herbert, Columbia, Medicine, Prostate-specific antigen, LM, Pharmaceutical industry, Advaxis

MONMOUTH JUNCTION, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate, in patients with biochemically recurrent (early) prostate cancer that is being conducted at Columbia University Irving Medical Center. Karie Runcie, MD, assistant professor of medicine, and Mark N. Stein, MD, associate professor of medicine, in the division of hematology/oncology at Columbia University Vagelos College of Physicians and Surgeons and members of the Herbert Irving Comprehensive Cancer Center, are the study’s principal and senior investigators, respectively.

Key Points: 
  • The study design of this phase 1 open-label dose escalation study for patients in both dose cohorts was presented at the 2022 ASCO Annual Meeting by Dr. Runcie (Abstract #: TPS5115).
  • The trial is currently expanding enrollment at the second dose level by up to six additional patients for a total of nine patients.
  • “We have completed evaluation of the dose-limiting-toxicity period for three patients at the second dose level for this Phase 1 trial of ADXS-504.
  • We look forward to analyzing the composite data to gain further insight into the safety and efficacy of this novel therapy.”

Assure Holdings Announces Acquisition of NervePro

Retrieved on: 
Friday, January 6, 2023
Surgeon, Columbia University Vagelos College of Physicians and Surgeons, Physician, USD, Assurant, Security (finance), Acquisition, Stanford University, Hospital, CBSI, Leonard Farlinger, Indian stock exchange, Roth Capital Partners, Spine, Management, Risk management

DENVER, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, is pleased to announce that on December 31, 2022, it completed the acquisition (the “Acquisition”) of substantially all of the assets of Neuroprotect Neuromonitoring, LLC, and certain of its affiliated entities (collectively, “NervePro”), a Colorado-based IONM service provider owned by J. Paul Elliott, M.D.

Key Points: 
  • DENVER, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, is pleased to announce that on December 31, 2022, it completed the acquisition (the “Acquisition”) of substantially all of the assets of Neuroprotect Neuromonitoring, LLC, and certain of its affiliated entities (collectively, “NervePro”), a Colorado-based IONM service provider owned by J. Paul Elliott, M.D.
  • Assure acquired specifically, accounts receivable for services after December 1, 2022, as well as NervePro’s material contracts, business relationships and other tangible assets.
  • In 2022, NervePro performed approximately 750 IONM managed cases covered by commercial insurance payors and employed three technologists supporting five surgeons at seven facilities.
  • Dr. Elliott commented, “We sought out Assure because we share a commitment to clinical excellence and delivering improved patient outcomes.

Egret Therapeutics Announces the Addition of Three New Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, January 3, 2023
Hospital, Neuroradiology, Cerebrovascular disease, Patient, Bleeding, Zilkha Neurogenetic Institute, Entrepreneurship, USC, The Society of Neurological Surgeons, Stanford University, Surgery, University, Keck School of Medicine of USC, Physician, Stroke, Society, George Washington University School of Medicine & Health Sciences, Vasospasm, Washington University School of Medicine, Columbia University Vagelos College of Physicians and Surgeons, Surgeon, Neurology, Washington University in St. Louis, Therapy, The Washington Campus Board of Directors, Barnes-Jewish Hospital, Columbia University, Science, Congress, SAB, Subarachnoid hemorrhage, Research, Degenerative disease, United States Air Force Scientific Advisory Board, Pharmaceutical industry, DRS, Neurosurgery

NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Egret Therapeutics, a clinical-stage company focused on the treatment of neurological diseases, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members:

Key Points: 
  • Egret Therapeutics, a portfolio company of Turret Capital Management, Announces the Addition of Three New Members.
  • In addition to having a busy surgical cerebrovascular practice, he runs a laboratory studying vasospasm.
  • The newly appointed members will work with the company's current SAB and with Egret Therapeutics' leadership team in bringing EGT-101 to the clinic.
  • "We look forward to their contributions as we progress our lead asset EGT-101 into the clinic next year," said Michael Lim, M.D., Chair of Neurological Surgery at Stanford University and Co-Founder and Chair of Egret Therapeutics' Scientific Advisory Board.

Columbia University, Bassett Healthcare Network Advance Collaboration with Cardiovascular Digital Medicine & Clinical Services

Retrieved on: 
Monday, November 28, 2022
Columbia University Irving Medical Center, Chief medical informatics officer, Heart, Cardiology, Columbia University, Hospital, Student, Partnership, U.S. News & World Report, Physician, Health, Patient, Columbia University Vagelos College of Physicians and Surgeons, Nursing, Fellows, MD, Education, Medical school, Digital technology, Research, NewYork-Presbyterian Hospital, News, Pharmaceutical industry, Medicine, Medical device, Central New York, Surgeon

Through digital technology, Bassett patients will have direct connections to a broad array of cardiovascular specialists in Manhattan.

Key Points: 
  • Through digital technology, Bassett patients will have direct connections to a broad array of cardiovascular specialists in Manhattan.
  • Our digital health strategies center on seamlessly connecting our patients in rural settings with world-class physicians, here on the Bassett campus and through our partnership with Columbia, says Dr.Tommy Ibrahim, President and CEO of Bassett Healthcare Network.
  • Bassett is committed to the ongoing expansion of our digital health capabilities into clinical services in cardiovascular care and beyond.
  • Bassett Healthcare Network is an integrated health system that provides care and services to people living in a 5,600 square mile region in upstate New York.

Phoenix Children's Names Associate Surgeon in Chief of Phoenix Children's Hospital - East Valley

Retrieved on: 
Tuesday, November 22, 2022
Dignity, Phoenix Children's Hospital, Bed, Pregnancy, Fellowship of the Royal Colleges of Surgeons, NICU, Physician, Parent, The Phoenix (magazine), CPN, Mayo Clinic, Leeuwen, Patient, Sports medicine, Dignity Health, American College, RN, Google Images, MD, Columbia University Vagelos College of Physicians and Surgeons, Fetus, MSN, Trauma, Nursing credentials and certifications, Health, Hospital, C.S. Mott Children's Hospital, Dignity Health St. Joseph's Hospital and Medical Center, Neonatology, University, Mercy Gilbert Medical Center, General surgery, Dentistry, Medicine, Surgeon

PHOENIX, Nov. 22, 2022 /PRNewswire/ -- Phoenix Children's recently named Kathleen van Leeuwen, MD, associate surgeon in chief of Phoenix Children's Hospital – East Valley, slated to open in 2023. Dr. van Leeuwen is recognized in her field as an outstanding physician and surgeon and, as a longtime resident and active community member in the East Valley, she has worked and lived alongside the families Phoenix Children's serves.

Key Points: 
  • PHOENIX, Nov. 22, 2022 /PRNewswire/ -- Phoenix Children's recently named Kathleen van Leeuwen, MD , associate surgeon in chief of Phoenix Children's Hospital East Valley, slated to open in 2023.
  • Phoenix Children's East Valley Campus encompasses the planned hospital and two specialty care clinic sites, one of which is already open.
  • Phoenix Children's Hospital East Valley is a 367,341-square-foot, state-of-the-art facility that will offer 48 pediatric beds, a 24-bed emergency department, surgical services and diagnostic imaging.
  • In addition, construction is underway at Phoenix Children's Hospital Arrowhead Campus in Glendale and Phoenix Children's Avondale Campus .